![Abdul Aziz](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/NMmz8CU21zNnnPYkM9n181AcRs3mRwOtzs39Y1jg.png)
Dr. Abdul Aziz Al Hammad
Radiation Oncologist
Prince Sultan Military Medical City
Saudi Arabia
![Abdul Aziz](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/NMmz8CU21zNnnPYkM9n181AcRs3mRwOtzs39Y1jg.png)
Dr. Abdul Aziz Al Hammad
Radiation Oncologist , Prince Sultan Military Medical City | Saudi Arabia
AbdulAziz AlHamad, MD FRCP (C)–Radiation Oncology is a Consultant of Radiation Oncologist at Prince Sultan Military Medical City, Saudi Arabia. Dr. Abdulaziz AlHamad 's top areas of care are X-ray, Ultrasound, Computed Tomography (CT), Nuclear medicine including positron emission tomography (PET), and magnetic resonance imaging (MRI) to diagnose and/or treat diseases.
Sessions by this speaker
Saturday, 2024-06-29
Session 2: Advanced Breast Cancer
11:00 - 14:00
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Saturday, 2024-06-29
Session 3: Advanced Breast Cancer
14:00 - 15:25
Saturday, 2024-06-29
Panel Discussion and Q&A
12:30 - 12:50
![AbdulRahman](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/x5HlHgrcx8TmwqgNqtBNT0lH4K8zFBcwbpPUg7OS.png)
Dr. AbdulRahman El Kinge
Consultant Medical Oncologist
Fakeeh University Hospital
United Arab Emirates
![AbdulRahman](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/x5HlHgrcx8TmwqgNqtBNT0lH4K8zFBcwbpPUg7OS.png)
Dr. AbdulRahman El Kinge
Consultant Medical Oncologist , Fakeeh University Hospital | United Arab Emirates
Dr. Abdul Rahman Agha El Kinge has an extensive experience in Medical Oncology. He has trained in Breast Cancer at the MD Anderson Cancer Center, USA, and he is also certified by the European Society of Medical Oncology. Dr. El Kinge is on the editorial board and a reviewer in multiple international medical journals. He is a Fellow of the American College of Physicians, and a member of local and international hematology and oncology societies. He has a keen interest in academics and as a result has multiple peer-reviewed publications. He has initiated and headed multiple oncology and hematology departments in KSA and UAE. He is the Chairperson of the yearly International Oncology and Supportive Care Congress. He has special interest and experience in Precision Medicine and Artificial intelligence in Cancer care.
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Saturday, 2024-06-29
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW
16:40 - 16:50
Saturday, 2024-06-29
Panel Discussion and Q&A
17:10 - 17:25
![Abdulrahman](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/5IgfuX3Han3zrq1C5UkNW8vj2SrSxnzFatiZDDJR.png)
Dr. Abdulrahman Sulaiman Bin Sumaida
Chief of Radiation Oncology
Tawam Hospital
United Arab Emirates
![Abdulrahman](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/5IgfuX3Han3zrq1C5UkNW8vj2SrSxnzFatiZDDJR.png)
Dr. Abdulrahman Sulaiman Bin Sumaida
Chief of Radiation Oncology , Tawam Hospital | United Arab Emirates
Dr Abdul Rahman Bin Sumaida is currently chief of Radiation Oncology at Tawam hospital AlAin, UAE. Dr Sumaida did his medical education From Milan University –Italy. He completed Radiation oncology residency training program from the Cape Town University. He did clinical Research fellowship in head and neck and Gastrointestinal malignancies from South Africa. He further completed Fellowship in SRS and SBRT from Halifax Canada. He is currently caring patient with head and neck and breast cancer .He is involved in multiple ongoing research. and he is involved in teaching junior staff, and involved in multiple committees
Sessions by this speaker
Saturday, 2024-06-29
Session 3: Early Breast Cancer
14:00 - 16:00
Saturday, 2024-06-29
Tawam Faculty
09:00 - 15:30
Lectures by this speaker
Saturday, 2024-06-29
Panel Discussion and Q&A
15:20 - 15:40
![Abdurahman](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/2LV4pBrRVus9fyr1UcN4uZ229WjWr7dBLWxls59f.png)
Dr. Abdurahman Ahmad Alloghbi
Assistant Professor, Department of Oncology
King Khalid University
Saudi Arabia
![Abdurahman](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/2LV4pBrRVus9fyr1UcN4uZ229WjWr7dBLWxls59f.png)
Dr. Abdurahman Ahmad Alloghbi
Assistant Professor, Department of Oncology , King Khalid University | Saudi Arabia
Dr. Abdurahman Alloghbi is currently an assistant professor at the School of Medicine at King Khalid University, Saudi Arabia. He holds the American board of Hematology Oncology, Internal Medicine, and Medical Quality. Dr. Abdurahman has numerous peer-reviewed publications and actively contributes to various health-related organizations. Furthermore, he has participated in numerous scientific conferences.
Lectures by this speaker
Sunday, 2024-06-30
Head and Neck Cancers Updates
14:50 - 15:00
Sunday, 2024-06-30
Panel Discussion and Q&A
15:20 - 15:30
![Aftab](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/cxTm3194ayOvRvBIB9QEhqSV0lV6NYOI7pJiIkSt.png)
Dr. Aftab Bhatti
Consultant Urological Surgeon
Tawam Hospital
United Arab Emirates
![Aftab](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/cxTm3194ayOvRvBIB9QEhqSV0lV6NYOI7pJiIkSt.png)
Dr. Aftab Bhatti
Consultant Urological Surgeon , Tawam Hospital | United Arab Emirates
Dr Aftab Ahmad Bhatti joined Tawam Hospital as a Consultant Urological Surgeon, after working in the United Kingdom for more than 25 years. The main focus of his work is Urological Oncology, Minimally Invasive Robotic Surgery and Laparoscopic surgery. Dr Aftab A Bhatti graduated from the University of Punjab, Rawalpindi Medical College, Pakistan. He completed his higher urological training from the Northern Deanery, Newcastle upon Tyne, UK. Dr Aftab Bhatti has published over 40 peer reviewed publications and his area of research interest includes kidney and prostate cancer. the area of his interest includes active surveillance for the low risk prostate cancer, surgical anatomy of prostate, refinements to surgical techniques for robotic assisted radical prostatectomy and surgical outcomes of the high risk prostate cancer and prognostic markers for the kidney cancer
Sessions by this speaker
Sunday, 2024-06-30
Session 6: Genitourinary Cancers
11:15 - 14:30
Saturday, 2024-06-29
Tawam Faculty
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
Panel Discussion and Q&A
12:25 - 13:00
![Ahmad](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/J8hCfXqUsBhCIi1MqqvKOIETVjm0AqB41dfdceTn.png)
Dr. Ahmad Raza
Staff Physician, Medical Oncology & Hematology, Oncology Institute
Cleveland Clinic Abu Dhabi
United Arab Emirates
![Ahmad](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/J8hCfXqUsBhCIi1MqqvKOIETVjm0AqB41dfdceTn.png)
Dr. Ahmad Raza
Staff Physician, Medical Oncology & Hematology, Oncology Institute , Cleveland Clinic Abu Dhabi | United Arab Emirates
Dr. Ahmad Raza, MD, MHA is a staff physician in the Oncology Institute at Cleveland Clinic Abu Dhabi. Prior to joining Cleveland Clinic Abu Dhabi, Dr. Raza served as Assistant Professor of Hematology and Oncology at Columbia University Irving Medical Center New York, US, and as Director, Cheryl R. Lindenbaum Comprehensive Cancer Center NewYork Presbyterian Hudson Valley Hospital, US. Dr. Raza completed his medical degree from Nishtar Medical College Multan, Pakistan. He is board certified in Internal Medicine, Medical Oncology and Hematology. He completed his fellowship in Hematology and Medical Oncology from the Division of Hematology Oncology and Transplant, University of Minnesota, US. He completed his Internal Medicine residency training from St Barnabas Hospital Weill Medical College of Cornell University New York, US, where he was named for the best resident of the year award. He earned a Master of Healthcare Administration (MHA) from the Division of Health Policy and Management, University of Minnesota School of Public Health, US.
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Saturday, 2024-06-29
Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial.
16:30 - 16:40
Saturday, 2024-06-29
Panel Discussion and Q&A
17:10 - 17:25
![Aladdin](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/oPWreqma9lkp5IYTPudezwZuGi0iY7LpqwlhvXob.png)
Dr. Aladdin Marraoui
Consultant and Chief of Medical Oncology
Gulf International Cancer Centre
United Arab Emirates
![Aladdin](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/oPWreqma9lkp5IYTPudezwZuGi0iY7LpqwlhvXob.png)
Dr. Aladdin Marraoui
Consultant and Chief of Medical Oncology , Gulf International Cancer Centre | United Arab Emirates
Dr. Maarraoui is Consultant and Chief of Hematology/Oncology at Gulf International Cancer Center in Abu Dhabi and Clinical Professor at Gulf Medical University, UAE. He previously served as Chief of Hematology/Oncology at Mafraq Hospital for 14 years. He graduated from Faculty of Medicine at Aleppo University/Syria. He did his Internal Medicine residency at Christ Hospital and Medical Center in Chicago, and his Hematology/Oncology fellowship at the University of Colorado Health Science Center in Denver, Colorado. He is American Board Certified and recertified in Internal medicine in 1992, 2002 and 2012, in Medical Oncology in 1999,2009 and 2019 and in Hematology in 1999, 2009 and 2019. Dr. Maarraoui authored and co-authored several abstracts and articles on Breast Cancer, Colon Cancer, Thyroid Cancer, lung cancer and Lymphoma focusing on these diseases in UAE.
Sessions by this speaker
Saturday, 2024-06-29
Breast Cancer Workshop 2 - Optimizing Therapeutic Selection and Sequencing Post CDK 4/6 Inhibition (Supported by Menarini Stemline)
17:00 - 18:00
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Saturday, 2024-06-29
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.
14:10 - 14:20
Saturday, 2024-06-29
Panel Discussion and Q&A
15:20 - 15:40
![Ali](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/QqZjHNHkrhaE8GvLHobEZYqmbfisozFApH9hkONw.png)
Dr. Ali Yousif
Oncology Fellow
Tawam Hospital
United Arab Emirates
![Ali](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/QqZjHNHkrhaE8GvLHobEZYqmbfisozFApH9hkONw.png)
Dr. Ali Yousif
Oncology Fellow , Tawam Hospital | United Arab Emirates
Oncology Fellow at Tawam Hospital
Sessions by this speaker
Saturday, 2024-06-29
Tawam Faculty
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
Panel Discussion and Q&A
15:20 - 15:30
![Aly](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/X1bd3WSbDQ1VYKGCrFjigfm6APPbjCDDFGOIIvGZ.png)
Dr. Aly Abdel Razek
Chairman and Executive Director
Gulf International Cancer Center
United Arab Emirates
![Aly](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/X1bd3WSbDQ1VYKGCrFjigfm6APPbjCDDFGOIIvGZ.png)
Dr. Aly Abdel Razek
Chairman and Executive Director , Gulf International Cancer Center | United Arab Emirates
Dr. Abdel Razek graduated from Cairo University. He completed his residency in 1976 at Washington University in St. Louis, Mo., USA. He is board certified in both Radiation Oncology and Pediatrics. He co-authored four text books in radiation oncology and contributed to many publications in oncology journals. He served on the national committee of the Southwest Oncology Group, Intergroup Ewings Sarcoma and National Wilms Tumor Committee. Dr. Abdel Razek is a Fellow of the American College of Radiation Oncology. He is president of Medical Resources International and Chairman and Executive Director of the Gulf International Cancer Center.
Sessions by this speaker
Saturday, 2024-06-29
Session 2: Advanced Breast Cancer
11:00 - 14:00
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Saturday, 2024-06-29
Panel Discussion and Q&A
12:30 - 12:50
![Amit](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/2XDcfNU47fS7pfBNp2cIUkM1qoq97CfSEEUG8STT.png)
Prof. Amit Bahl
Consultant Clinical Oncologist, Director of Oncology
Bristol Cancer Institute, University Hospitals Bristol
United Kingdom
![Amit](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/2XDcfNU47fS7pfBNp2cIUkM1qoq97CfSEEUG8STT.png)
Prof. Amit Bahl
Consultant Clinical Oncologist, Director of Oncology , Bristol Cancer Institute, University Hospitals Bristol | United Kingdom
Amit Bahl is Consultant Clinical Oncologist at Bristol Cancer Institute, University Hospitals Bristol, Bristol, UK. Prof. Bahl became Member of the Royal College of Physicians (RCP) and trained in Clinical Oncology, achieving Fellowships of the RCP and of the Royal College of Radiologists (RCR). He has also been an expert adviser to the National Institute for Health and Care Excellence (NICE) for technology appraisals on new drugs. Prof. Bahl is actively involved in research and leads the brachytherapy and robotics research programme in prostate cancer. He is the Clinical Co-lead for National Kidney Cancer Audit and Chairperson of British Uro-oncology Group.
Sessions by this speaker
Saturday, 2024-06-29
International Speakers
09:00 - 15:30
Saturday, 2024-06-29
GU Workshop - Theranostics: The future of Prostate cancer treatment is here! (Supported by Novartis)
11:30 - 12:30
Lectures by this speaker
Sunday, 2024-06-30
Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).
11:25 - 11:35
Sunday, 2024-06-30
Panel Discussion and Q&A
12:25 - 13:00
Sunday, 2024-06-30
Latest Updates in the Management of mHSPC (Satellite Symposium by Janssen)
12:05 - 12:25
Saturday, 2024-06-29
PSMA radioligand therapy: Efficacy and QOL data
11:35 - 11:45
Friday, 2024-06-28
Prostate Cancer
14:30 - 14:45
![Ammar](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/J5JeQJ3HpPenSfX2pQqelP8buu9I0SA1wK1FkoEU.png)
Dr. Ammar Madani
Consultant Medical Oncologist
National Center for Cancer Care and Research
Qatar
![Ammar](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/J5JeQJ3HpPenSfX2pQqelP8buu9I0SA1wK1FkoEU.png)
Dr. Ammar Madani
Consultant Medical Oncologist , National Center for Cancer Care and Research | Qatar
Dr. Ammar Madani is a Consultant Medical Oncologist at National Centre for Cancer Care and Research, Doha QATAR. He graduated from Rajiv Gandhi University, India in 2009. He completed his Internal Medicine Residency and Oncology Fellowship from Hamad Medical Corporation QATAR. He also obtained his MRCP(UK) and MRCP in Medical Oncology and ESMO Certificate. His Field of Interest include Thoracic, GenitoUrinary and Head and Neck Cancers.
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Sunday, 2024-06-30
Lung Cancer Workshop 2: Transforming the Current Treatment Paradigm in The Management of EGFRm NSCLC for Better Survival Outcomes (Supported by AstraZeneca)
14:30 - 16:00
Sunday, 2024-06-30
Session 6: Genitourinary Cancers
11:15 - 14:30
Lectures by this speaker
Sunday, 2024-06-30
Panel Discussion and Q&A
10:25 - 10:55
Sunday, 2024-06-30
Panel Discussion
15:20 - 15:55
![Anwar](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/d0PXLfhZ2Y8kp6hSPYm8bxKqkV3LHSAXnd6m8pks.png)
Dr. Anwar Alnouri
Consultant Medical Oncologist
Kuwait Cancer Control Centre
Kuwait
![Anwar](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/d0PXLfhZ2Y8kp6hSPYm8bxKqkV3LHSAXnd6m8pks.png)
Dr. Anwar Alnouri
Consultant Medical Oncologist , Kuwait Cancer Control Centre | Kuwait
Dr. Anwar Alnouri is currently a Consultant Medical Oncology at Kuwait Cancer Control Centre (KCCC). He did Clinical Research in Medical Oncology Fellowship (Breast) at McGill University and he is Associate Member of the American Society of Clinical Oncology. He was also a Fellow of the Royal College of Physicians & Surgeons of Canada and he has the Canadian Board Internal Medicine (FRCPC).
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Saturday, 2024-06-29
Breast Cancer Workshop 2 - Optimizing Therapeutic Selection and Sequencing Post CDK 4/6 Inhibition (Supported by Menarini Stemline)
17:00 - 18:00
Sunday, 2024-06-30
Breast Cancer Workshop 3 - Exploring the potential of ADCs in Breast Cancer (Supported by Gilead)
09:30 - 10:30
Lectures by this speaker
Saturday, 2024-06-29
Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.
11:40 - 11:50
Saturday, 2024-06-29
Panel Discussion and Q&A
12:30 - 12:50
Sunday, 2024-06-30
Debate Topic: What should be the Standard of Care Treatment for Patients with 2L Metastatic HER2 Negative and how to Sequence Clinical Scenario
09:40 - 10:00
Sunday, 2024-06-30
Improving the Lives of Patients with mTNBC and Metastatic HR+ Breast Cancer: Efficacy Standpoint
09:30 - 09:40
![Aswatha](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/wlxxAP3hNKrWvmeDPd8iESYrA0yiq6vWMLMyZ609.png)
Dr. Aswatha Ramesh
Consultant in Surgical Oncology and Colorectal Surgery
Tawam Hospital
United Arab Emirates
![Aswatha](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/wlxxAP3hNKrWvmeDPd8iESYrA0yiq6vWMLMyZ609.png)
Dr. Aswatha Ramesh
Consultant in Surgical Oncology and Colorectal Surgery , Tawam Hospital | United Arab Emirates
Dr. Aswatha Ramesh, Consultant in Surgical Oncology and Colorectal Surgery, and member of the Royal College of Surgeons and the Association of Coloproctology of Great Britain and Ireland. He has held various senior positions during his extensive years of expertise, including Chief of General Surgery at Manchester University NHS Hospital. Furthermore, Dr. Ramesh has invested in medical advancement with research focusing on the application of Artificial Intelligence in predicting outcomes of Breast and Colorectal Surgery. Now, he implements his leadership and clinical expertise in collaboration with Tawam Hospital to achieve our quest for the utmost healthcare experience
Sessions by this speaker
Saturday, 2024-06-29
Tawam Faculty
09:00 - 15:30
Saturday, 2024-06-29
Session 4: Gastrointestinal Cancers
16:00 - 17:50
Lectures by this speaker
Saturday, 2024-06-29
Panel Discussion and Q&A
17:10 - 17:25
Saturday, 2024-06-29
Primary outcome analysis of the ORCHESTRA trial: A randomized phase III trial of additional tumor debulking to first-line palliative systemic therapy for patients with multiorgan metastatic colorectal cancer.
16:00 - 16:10
![Aydah](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/tiovBseVIhYWSOKIFCdOlOSMNVMzbc4FITy6eVjT.png)
Dr. Aydah Awadhi
Consultant Physician
Tawam Hospital
United Arab Emirates
![Aydah](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/tiovBseVIhYWSOKIFCdOlOSMNVMzbc4FITy6eVjT.png)
Dr. Aydah Awadhi
Consultant Physician , Tawam Hospital | United Arab Emirates
Dr. Aydah Al Awadhi is a Medical Oncologist and Quality Officer in Oncology at Tawam Hospital. She graduated from the MD Anderson Hematology and Medical Oncology fellowship in 2019. Her main interest is in breast cancer and she published several peer review research articles and multiple book chapters in breast cancer.
Sessions by this speaker
Saturday, 2024-06-29
Session 2: Advanced Breast Cancer
11:00 - 14:00
Saturday, 2024-06-29
Tawam Faculty
09:00 - 15:30
Sunday, 2024-06-30
Breast Cancer Workshop 3 - Exploring the potential of ADCs in Breast Cancer (Supported by Gilead)
09:30 - 10:30
Lectures by this speaker
Saturday, 2024-06-29
Panel Discussion and Q&A
12:30 - 12:50
Saturday, 2024-06-29
Escalation in the Era of CDK4/6i + ET for HR+ HER2- eBC: Prognosis-Based Approach (Satellite Symposium by Novartis)
14:40 - 15:00
Saturday, 2024-06-29
Panel Discussion and Q&A
15:20 - 15:40
![Basel](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/aTzippBVuNu4AjUSqaKRE69ri0NchZPbUWxy0xFh.png)
Dr. Basel Al Haj Ali
Consultant Hemato-Oncologist
Sheikh Khalifa Specialty Hospital, UAE
United Arab Emirates
![Basel](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/aTzippBVuNu4AjUSqaKRE69ri0NchZPbUWxy0xFh.png)
Dr. Basel Al Haj Ali
Consultant Hemato-Oncologist , Sheikh Khalifa Specialty Hospital, UAE | United Arab Emirates
Dr. Basel Al Haj is a Consultant Hemato-Oncologist at Sheikh Khalifa Specialty Hospital.
Sessions by this speaker
Sunday, 2024-06-30
Session 7: Practice Changing Data
14:30 - 15:35
Saturday, 2024-06-29
Breast Cancer Workshop 1- HER-2 Positive Early Breast Cancer - Optimising Treatment Options (Supported by Roche)
16:00 - 17:00
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
Panel Discussion and Q&A
15:20 - 15:30
![Bassel](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/C7d3WUELLgwPR8Ub4PCHy4ZIdpEoqlxQahngnSQo.png)
Dr. Bassel Jallad
Staff Physician, Medical Oncology & Hematology, Oncology Institute
Cleveland Clinic Abu Dhabi
United Arab Emirates
![Bassel](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/C7d3WUELLgwPR8Ub4PCHy4ZIdpEoqlxQahngnSQo.png)
Dr. Bassel Jallad
Staff Physician, Medical Oncology & Hematology, Oncology Institute , Cleveland Clinic Abu Dhabi | United Arab Emirates
Bassel Jallad, MD, CPE is a Staff Physician at Cleveland Clinic Abu Dhabi and Adjunct Assistant Professor, School of Medicine, at St. Louis University, St Louis, Missouri, USA. Prior to joining Cleveland Clinic Abu Dhabi, Dr. Jallad was the Associate Director of Medical Oncology Fellowship Program at St Louis University in St Louis, Missouri and the Medical Director of Medical Oncology Service Line at Blessing Health System in Quincy, Illinois, USA. Dr. Jallad received his medical degree from Jordan University of Science and Technology, Irbid, Jordan, and completed his residency at the University of Illinois, Chicago, USA. He completed his fellowship at the Henry Ford Hospital, Wayne State University, Michigan, USA. Dr. Jallad is triple American Board Certified in Internal Medicine , Medical Oncology and Hematology.
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Saturday, 2024-06-29
Breast Cancer Workshop 2 - Optimizing Therapeutic Selection and Sequencing Post CDK 4/6 Inhibition (Supported by Menarini Stemline)
17:00 - 18:00
Lectures by this speaker
Saturday, 2024-06-29
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.
12:00 - 12:10
Sunday, 2024-06-30
Panel Discussion and Q&A
15:20 - 15:30
Saturday, 2024-06-29
Panel Discussion and Q&A
12:30 - 12:50
Saturday, 2024-06-29
ER+ve: Disease Mechanisms of Resistance
17:05 - 17:15
![Cherian](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/e2JUM2Mh9L1RSnx5hF0T7pgYyFQRWvKsamQNnOfd.png)
Dr. Cherian Thampy
Consultant Medical Oncologist
NMC Hospital
United Arab Emirates
![Cherian](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/e2JUM2Mh9L1RSnx5hF0T7pgYyFQRWvKsamQNnOfd.png)
Dr. Cherian Thampy
Consultant Medical Oncologist , NMC Hospital | United Arab Emirates
Dr. Cherian is a medical oncologist at NMC with 8 years’ experience in Oncology from the prestigious KIMS - Cancer Center in Trivandrum, India where he was working as Associate Consultant in Medical Oncology since 2015. Prior to KIMS, Dr. Cherian was working at the world renowned Cancer Institute, Chennai, India as an Assistant Professor of Medical Oncology. Dr. Cherian Thampy key areas of interest are: Gastrointestinal Oncology, Lymphomas, Breast Cancers and Immunotherapy He has also worked at SRMC, Chennai, India and Lakeshore Hospital, Kochi, India. Dr. Cherian Thampy completed MBBS from K.S. Hegde Medical Academy, Mangalore and thereafter obtained his MD in General Medicine from Sri Ramachandra Medical College, Chennai. He went on to complete his DM in Medical Oncology from The Cancer Institute, Chennai, India. Dr. Cherian Thampy successfully completed his MRCP Speciality certification in medical oncology. It is certified by the federation of royal college of physicians of United Kingdom and the association of cancer physicians.
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Sunday, 2024-06-30
Lung Cancer Workshop 1 - Targeted therapy for a NSCLC- Focus on ALK Inhibition (Supported by Pfizer)
11:30 - 12:30
Lectures by this speaker
Sunday, 2024-06-30
Melanoma / Skin Cancers Updates
15:10 - 15:20
Sunday, 2024-06-30
Panel Discussion and Q&A
15:20 - 15:30
Sunday, 2024-06-30
Navigating the Treatment Landscape: Case Presentation
12:00 - 12:20
![Cornelius](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/uobsauI46RbTM2wTOFMPSvzXxVGBqyOMhqh3N2wI.png)
Prof. Cornelius Waller
Professor, Department of Internal Medicine, Hematology, Oncology and Stem Cell Transplantation
Freiburg University Medical Center
Germany
![Cornelius](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/uobsauI46RbTM2wTOFMPSvzXxVGBqyOMhqh3N2wI.png)
Prof. Cornelius Waller
Professor, Department of Internal Medicine, Hematology, Oncology and Stem Cell Transplantation , Freiburg University Medical Center | Germany
Dr. Cornelius Waller had his medical training at the University of Tuebingen, Germany, St. Bartholomew's Hospital, London, and the Universitätsspital Zurich, Switzerland from 19830-1990. In the same year, he obtained his medical license and completed his doctoral thesis on “In Vivo validation of image-directed Doppler measurements of superior mesenteric artery blood flow." Between 1990-2000, he completed his medical residency training at the University Hospital of Freiburg, Germany. He also pursued two postdoctoral fellowships at the Department of Molecular Biology at Princeton University, Princeton, USA (1992-1994) and at the Department of Cancer Biology at the Cleveland Clinic Foundation, Cleveland, USA (1994). In November 1994, Cornelius Waller continued his residency at the Department of Haematology and Oncology at the University Medical Center Freiburg, Germany. He has board certifications for Internal Medicine (2000), Haematology and General Oncology (2001), and Palliative Care (2007). In 2000, he completed his "Habilitation" on "Mobilization and Purging of Autologous Hematopoietic Stem Cells for Transplantation After High-dose Chemotherapy in Malignant Disease" and was awarded the Academic Teaching License by the University of Freiburg, Germany. He was promoted to Associate Professor in 2006. Since 2007 Dr. Waller is an attending physician and responsible coordinator of the Freiburg University Lung Cancer Center. He is also an attending physician for the Urogenital Cancer Center and at the Department of Haematology, Oncology, and Stem Cell Transplantation. He has been an investigator, co-investigator, and principal investigator in numerous clinical trials with a special focus on lung and breast cancer, testicular cancer, supportive care, and biosimilar development since 1994. He is a member of the German Cancer Society, the German Society of Haematology and Oncology, the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the German Society of Internal Medicine.
Sessions by this speaker
Saturday, 2024-06-29
International Speakers
09:00 - 15:30
Lectures by this speaker
Saturday, 2024-06-29
Osimertinib after definitive CRT in patients with unresectable stage III EGFRm NSCLC: Primary results of the phase 3 LAURA study.
10:00 - 10:10
Saturday, 2024-06-29
Panel Discussion and Q&A
10:20 - 10:40
![Deborah](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/VlFH0gx4TRc9ERBP37Hb8VZMD5hpHlQsP68MPkZI.png)
Dr. Deborah Mukherji
Consultant Medical Oncologist
Clemenceau Medical Center Dubai
United Arab Emirates
![Deborah](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/VlFH0gx4TRc9ERBP37Hb8VZMD5hpHlQsP68MPkZI.png)
Dr. Deborah Mukherji
Consultant Medical Oncologist , Clemenceau Medical Center Dubai | United Arab Emirates
Dr Mukherji completed her advanced specialty training in Medical Oncology at Guys and St Thomas’s NHS Foundation Trust, London UK and was awarded a Post-Graduate Diploma in Oncology from the Institute of Cancer Research, University of London in 2011. On completion of her advanced specialty training Dr Mukherji joined the Royal Marsden Hospital London specializing in clinical research and drug development with a focus on prostate cancer. Dr Mukherji joined the faculty of the American University of Beirut, Lebanon in June 2012 and currently an associate professor of clinical medicine, she joined Clemenceau Medical Center Dubai UAE as a consultant medical oncologist in October 2022. Dr Mukherji specializes in GI and GU medical oncology. She is currently an ESMO faculty member for the genitourinary tumors prostate group and a panel member for the Advanced Prostate Cancer Consensus Conference (APCCC).
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
11:35 - 11:45
Sunday, 2024-06-30
Panel Discussion and Q&A
12:25 - 13:00
![Diaeddine](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/s251n2Nb3ol0t5WO8971hUcArV7SKih8rMF51eqn.png)
Dr. Diaeddine Trad
Consultant Medical Oncologist
Tawam Hospital
United Arab Emirates
![Diaeddine](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/s251n2Nb3ol0t5WO8971hUcArV7SKih8rMF51eqn.png)
Dr. Diaeddine Trad
Consultant Medical Oncologist , Tawam Hospital | United Arab Emirates
Dr. Diaeddine Trad is a Consultant of Medical Oncology, at Tawam Hospital, in Al Ain, UAE. He is a member of the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). He is an investigator in several ongoing clinical trials. Dr. Trad is certified as a specialist in internal medicine, hematology and oncology by the Lebanese Ministry of Health. His research interests include; non-small cell lung adenocarcinoma and locally advanced breast cancer. Dr. Trad was a speaker in many international conferences and forums.
Sessions by this speaker
Saturday, 2024-06-29
Session 1: Plenary
09:40 - 11:00
Saturday, 2024-06-29
Session 4: Gastrointestinal Cancers
16:00 - 17:50
Saturday, 2024-06-29
Tawam Faculty
09:00 - 15:30
Sunday, 2024-06-30
Breast Cancer Workshop 3 - Exploring the potential of ADCs in Breast Cancer (Supported by Gilead)
09:30 - 10:30
Sunday, 2024-06-30
Lung Cancer Workshop 1 - Targeted therapy for a NSCLC- Focus on ALK Inhibition (Supported by Pfizer)
11:30 - 12:30
Sunday, 2024-06-30
Lung Cancer Workshop 2: Transforming the Current Treatment Paradigm in The Management of EGFRm NSCLC for Better Survival Outcomes (Supported by AstraZeneca)
14:30 - 16:00
Lectures by this speaker
Saturday, 2024-06-29
Panel Discussion and Q&A
10:20 - 10:40
Saturday, 2024-06-29
Panel Discussion and Q&A
17:10 - 17:25
Sunday, 2024-06-30
Setting the new standard in the management of early and locally advanced EGFRm NSCLC
14:30 - 14:40
Sunday, 2024-06-30
Debate Topic: Balancing Innovation and Safety: Navigating the Safety Seas of ADCs in Breast Cancer Treatment Clinical Scenario
10:10 - 10:30
Sunday, 2024-06-30
Targeted Therapy for aNSCLC ALK Inhibition: Start Strong for Front Line Therapy
11:30 - 11:50
![Dina](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/b0h5iEgxlBTrTPwYWffUT54nSbvcKzW0Jj6OKZm4.png)
Dr. Dina Hamza
Consultant Medical Oncologist
Dubai Health Authority
United Arab Emirates
![Dina](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/b0h5iEgxlBTrTPwYWffUT54nSbvcKzW0Jj6OKZm4.png)
Dr. Dina Hamza
Consultant Medical Oncologist , Dubai Health Authority | United Arab Emirates
Consultant medical oncology Completed training in Oncology 2001 National Cancer Institute - Masters degree in clinical Oncology Cairo University - Fellowship from ULM university Germany - European Board certified from European school of Oncology worked in different health care systems Working in Dubai since 2008 Had more than 20 publications in oncology the most citation was for the MENA Breast Guidelines; acknowledged by e-cancer search foundation Member of the most dynamic, scientific and leading organization; EOS
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Sunday, 2024-06-30
Breast Cancer Workshop 3 - Exploring the potential of ADCs in Breast Cancer (Supported by Gilead)
09:30 - 10:30
Sunday, 2024-06-30
Lung Cancer Workshop 1 - Targeted therapy for a NSCLC- Focus on ALK Inhibition (Supported by Pfizer)
11:30 - 12:30
Sunday, 2024-06-30
Lung Cancer Workshop 2: Transforming the Current Treatment Paradigm in The Management of EGFRm NSCLC for Better Survival Outcomes (Supported by AstraZeneca)
14:30 - 16:00
Lectures by this speaker
Saturday, 2024-06-29
Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC).
16:20 - 16:30
Saturday, 2024-06-29
Panel Discussion and Q&A
17:10 - 17:25
Sunday, 2024-06-30
Translating evidence into clinical practice: redefining survival in advanced EGFR NSCLC
15:15 - 15:20
Sunday, 2024-06-30
Debate Topic: Balancing Innovation and Safety: Navigating the Safety Seas of ADCs in Breast Cancer Treatment Clinical Scenario
10:10 - 10:30
Sunday, 2024-06-30
Targeted Therapy for aNSCLC ALK Inhibition: Start Strong for Front Line Therapy
11:30 - 11:50
Saturday, 2024-06-29
Improving Survival Outcomes in 1L HR+ HER2- Aggressive Disease & Visceral Metastasis Patients (Satellite Symposium by Novartis)
12:10 - 12:30
![Ehab](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/3PRCqC7HMfuBNKwAmBdBdaZkWlJTvRX1w6EIQ7qo.png)
Prof. Ehab Abdou
Consultant Medical Oncologist
Al Hada Armed Forces Hospital
Saudi Arabia
![Ehab](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/3PRCqC7HMfuBNKwAmBdBdaZkWlJTvRX1w6EIQ7qo.png)
Prof. Ehab Abdou
Consultant Medical Oncologist , Al Hada Armed Forces Hospital | Saudi Arabia
Prof. Ehab Abdou is a professor of clinical oncology at Al-Azhar university , Cairo, Egypt Currently, he is a consultant medical oncologist at Al-Hada Armed Forces Hospital. He has joined many centers of oncology centers in Egypt , KSA , Kuwait and Bahrain. He is interested in GU, Gynecological head and neck cancer management and research.
Sessions by this speaker
Saturday, 2024-06-29
Session 4: Gastrointestinal Cancers
16:00 - 17:50
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Saturday, 2024-06-29
Panel Discussion and Q&A
17:10 - 17:25
![Emad Anwar](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/xn9DNzVs3SC5La7aMsb7jTJTTcJw40BpPYxW0EzI.png)
Dr. Emad Anwar Dawoud
Consultant Clinical Oncologist
Tawam Hospital
United Arab Emirates
![Emad Anwar](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/xn9DNzVs3SC5La7aMsb7jTJTTcJw40BpPYxW0EzI.png)
Dr. Emad Anwar Dawoud
Consultant Clinical Oncologist , Tawam Hospital | United Arab Emirates
Dr. Emad Dawoud is a Consultant Medical Oncologist in Oncology department at Tawam hospital UAE, and Assistant professor of clinical oncology in Al Azhar University Cairo, Egypt . Dr. Dawoud completed his MD, PhD in clinical oncology since 2010, and Federation of Royal Colleague of physician of United Kingdom medical oncology speciality since 2012 and Master Degree in clinical Oncology since 2003. Dr Dawoud has been graduated from the Al Azhar University in Cairo Egypt since 1997 . Dr. Dawoud has been principal investigator and co- investigator for more than 50 clinical trials and abstract published per reviewed journals and he is a member of various associations such as ASCO, ESMO, ESTRO.
Sessions by this speaker
Sunday, 2024-06-30
Session 5: Lung Cancer
09:00 - 11:15
Saturday, 2024-06-29
Tawam Faculty
09:00 - 15:30
Saturday, 2024-06-29
Breast Cancer Workshop 1- HER-2 Positive Early Breast Cancer - Optimising Treatment Options (Supported by Roche)
16:00 - 17:00
Sunday, 2024-06-30
Lung Cancer Workshop 1 - Targeted therapy for a NSCLC- Focus on ALK Inhibition (Supported by Pfizer)
11:30 - 12:30
Sunday, 2024-06-30
Lung Cancer Workshop 2: Transforming the Current Treatment Paradigm in The Management of EGFRm NSCLC for Better Survival Outcomes (Supported by AstraZeneca)
14:30 - 16:00
Lectures by this speaker
Saturday, 2024-06-29
A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.
14:00 - 14:10
Sunday, 2024-06-30
Panel Discussion and Q&A
10:25 - 10:55
Saturday, 2024-06-29
Improving Survival Outcomes in 1L HR+ HER2- Aggressive Disease & Visceral Metastasis Patients (Satellite Symposium by Novartis)
12:10 - 12:30
Saturday, 2024-06-29
Panel Discussion and Q&A
12:30 - 12:50
Saturday, 2024-06-29
Panel Discussion and Q&A
15:20 - 15:40
Saturday, 2024-06-29
Introduction
16:00 - 16:05
Saturday, 2024-06-29
Dual Anti-HER2 Blockade in Adjuvant Setting: Evidence and Perceptions
16:25 - 16:30
Sunday, 2024-06-30
Evolving treatment landscape in the management of advanced EGFRm NSCLC
15:00 - 15:15
Sunday, 2024-06-30
Questions and Conclusion
12:20 - 12:30
![Ernest](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/f98NOd9InJf8yh7hnwsH3QOoLr8d15puX82fCXCo.png)
Prof. Ernest Luiten
Chief Breast Surgery Department
Tawam Hospital
United Arab Emirates
![Ernest](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/f98NOd9InJf8yh7hnwsH3QOoLr8d15puX82fCXCo.png)
Prof. Ernest Luiten
Chief Breast Surgery Department , Tawam Hospital | United Arab Emirates
Doctor Ernest J.T. Luiten (MD PhD) is a Dutch board certified General and Oncologic surgeon with more than 27 years of experience as a consultant surgeon and a former board member of the Dutch Oncologic Surgical Society. He is specialized in breast cancer surgery with special interest in oncoplastic breast conserving procedures, innovative axillary surgery as well as genetic expression profiling. Doctor Luiten is (co-)author of up to 70 publications in international medical journals and principal investigator of several large multi-center RCT’s including the recently finished RISAS study (PMID: 28487053). Besides that he is also member of the Medical Service of the Automobile Club of Monaco for more than 20 years and involved with the Grand Prix Formula One of Monaco.He recently moved to Abu Dhabi UAE to join the medical staff of the Tawam Hospital in Al Ain.
Sessions by this speaker
Saturday, 2024-06-29
Session 3: Early Breast Cancer
14:00 - 16:00
Saturday, 2024-06-29
Tawam Faculty
09:00 - 15:30
![Esam](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/D6J48BwjWc3PXC8mN0Lw8Zb7teefXlICSizw05Gs.png)
Dr. Esam Murshid
Consultant Medical Oncologist
Prince Sultan Medical Military City
Saudi Arabia
![Esam](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/D6J48BwjWc3PXC8mN0Lw8Zb7teefXlICSizw05Gs.png)
Dr. Esam Murshid
Consultant Medical Oncologist , Prince Sultan Medical Military City | Saudi Arabia
Dr Esam Murshid is a Consultant Medical Oncologist and Director Oncology Center at Prince Sultan Medical Military City, Riyadh, Kingdom of Saudi Arabia. He was a Fellow of the Royal College of Radiologist, Faculty of Clinical Oncology, London UK and a Co-Founder and past president of the Saudi Oncology Society (SOS). He is also a Member of the of The Saudi National Oncology institute Advisory Board Saudi Cancer Registry Board and the Chairman of the Ministry of Defense Health Services Department Oncology Services Permanent Supervisory Committee.
Sessions by this speaker
Saturday, 2024-06-29
Session 3: Early Breast Cancer
14:00 - 16:00
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Saturday, 2024-06-29
Panel Discussion and Q&A
15:20 - 15:40
![Faisal](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/Aqg49korbxU4EptPiug0mzlai37xqgIkY6mdTdoa.png)
Dr. Faisal Azam
Consultant Medical Oncologist
King Fahad Specialist Hospital
Saudi Arabia
![Faisal](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/Aqg49korbxU4EptPiug0mzlai37xqgIkY6mdTdoa.png)
Dr. Faisal Azam
Consultant Medical Oncologist , King Fahad Specialist Hospital | Saudi Arabia
Dr Faisal Azam is a consultant medical oncologist at King Fahad specialist Hospital Dammam (KFSHD) and previously worked as a consultant at Betsi cadwaladr university board Hospital in United Kingdom. He has special interest in GU cancers, Gynae cancers, sarcomas and skin cancers. He had completed a formal training in Medical oncology at Clatterbridge cancer centre, Liverpool leading to a CCT and a research training at Oxford University. His qualifications include FRCP, CCT in medical oncology, MRCP-UK, MRCP-Ireland, PG-Dip in Oncology from Birmingham University and PG-Cert in Medical education from Edgehill Liverpool University. He is currently a research in-charge for Oncology, an IRB (Investigational review board) member and FTC (Formulary therapeutics committee) member at KFSHD. He has published more than 40 articles in peer-reviewed journals and did presentations in many international, national and regional oncology conferences.
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.
11:45 - 11:55
Sunday, 2024-06-30
Panel Discussion and Q&A
12:25 - 13:00
![Fathi](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/X9MZGX6xOTyh59Fn0q6B0T1Q9JWyK0SHIMU37qiQ.png)
Dr. Fathi Azribi
Consultant Medical Oncologist
American Hospital Dubai
United Arab Emirates
![Fathi](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/X9MZGX6xOTyh59Fn0q6B0T1Q9JWyK0SHIMU37qiQ.png)
Dr. Fathi Azribi
Consultant Medical Oncologist , American Hospital Dubai | United Arab Emirates
Dr Fathi Azribi is a Consultant Medical Oncologist. He graduated from Tripoli University, Libya, then completed specialty training in Oncology in the UK and obtained a Certificate of Completion of Training in Medical Oncology. His main interest is in thoracic, breast, gynaecological and gastrointestinal malignancies, with expertise in treatment with chemotherapy, immunotherapy, hormonal, and targeted therapy. He published several papers and abstracts in peer reviewed journals. He also founded the first Medical Oncology Fellowship program in the UAE.
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Saturday, 2024-06-29
Breast Cancer Workshop 2 - Optimizing Therapeutic Selection and Sequencing Post CDK 4/6 Inhibition (Supported by Menarini Stemline)
17:00 - 18:00
Lectures by this speaker
Saturday, 2024-06-29
A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial.
14:20 - 14:30
Saturday, 2024-06-29
Panel Discussion and Q&A
15:20 - 15:40
![Fharat](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/Dy7fozeVWMoubxFtWHp1sJ831X00UvLF5DvFvrp3.png)
Dr. Fharat Raja
Consultant Medical Oncologist
North Middlesex University Hospital NHS Trust
United Kingdom
![Fharat](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/Dy7fozeVWMoubxFtWHp1sJ831X00UvLF5DvFvrp3.png)
Dr. Fharat Raja
Consultant Medical Oncologist , North Middlesex University Hospital NHS Trust | United Kingdom
Dr Raja graduated in medicine from Oxford University. She undertook her post-graduate training in medical oncology at University College London Hospital and Mount Vernon Cancer centre. She was a Clinical Fellow at the MRC Clinical Trials Unit and UCL Cancer Trials Centre from 2009-2013 and retains good links with these centres. Dr Raja is currently a consultant Medical Oncologist at UCLH and North Middlesex University Hospital where she specialises in Breast Cancer and Acute Oncology. She is the Clinical Lead for Acute Oncology at the North Middlesex hospital as well as the Principal Investigator of a number of national and international trials. She has also published in a number of peer reviewed journals including the Lancet, Annals of Oncology and British Journal of Cancer.
Sessions by this speaker
Saturday, 2024-06-29
International Speakers
09:00 - 15:30
Lectures by this speaker
Saturday, 2024-06-29
First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2‑negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses.
11:20 - 11:30
Saturday, 2024-06-29
Abemaciclib Consistently Giving Hope for HR+ HER2- Hight Risk Breast Cancer Patients (Satellite Symposium by Lilly)
15:00 - 15:20
Saturday, 2024-06-29
Panel Discussion and Q&A
12:30 - 12:50
Saturday, 2024-06-29
Panel Discussion and Q&A
15:20 - 15:40
![Giannis](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/I2fUw5bHfA2Bnh3A0cMXSFTeaF9eeF8lUzkXIRZx.png)
Prof. Giannis Mountzios
Consultant Medical Oncologist
Air Force General Hospital - Athens
Greece
![Giannis](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/I2fUw5bHfA2Bnh3A0cMXSFTeaF9eeF8lUzkXIRZx.png)
Prof. Giannis Mountzios
Consultant Medical Oncologist , Air Force General Hospital - Athens | Greece
"Dr Giannis Mountzios (MD, MSc, PhD) was born in Larissa, Greece, in 1974. He obtained his Medical Degree (MD) from the Aristotle University of Thessaloniki in 1998 with a scholarship from the Greek Ministry of Education and graduated from the Hellenic Military Medical Academy the same year. He completed his residency in Internal Medicine at the 251 Air force General Hospital of Athens and in Medical Oncology at the University of Athens School of Medicine, “Alexandra” University Hospital. He then obtained a Master (MSc) in Translational and Clinical Research in Oncology from the Institut Gustave-Roussy and the University Paris XI (Paris-Sud), France, in 2007 and became board-specified in Medical Oncology in 2009. In 2010 he obtained his PhD in Medical Oncology from the University of Athens School of Medicine. Dr Mountzios is currently working as a consultant Medical Oncologist at the Department of Medical Oncology in the Air force General Hospital in Athens. Dr Mountzios has received fellowships from the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO) and the Hellenic Society for Medical Oncology (HESMO). He is a member of the Board of Directors of HESMO and previous chair of the HESMO young medical oncologists committee. From 2012 to 2014, Dr Mountzios was a member of the ESMO Young Oncologists Committee. Since 2019, he is a member of the ESMO Educational Publications Working Group."
Sessions by this speaker
Saturday, 2024-06-29
International Speakers
09:00 - 15:30
Sunday, 2024-06-30
Lung Cancer Workshop 2: Transforming the Current Treatment Paradigm in The Management of EGFRm NSCLC for Better Survival Outcomes (Supported by AstraZeneca)
14:30 - 16:00
Lectures by this speaker
Sunday, 2024-06-30
Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.
09:20 - 09:30
Sunday, 2024-06-30
Panel Discussion and Q&A
10:25 - 10:55
Sunday, 2024-06-30
Evolving treatment landscape in the management of advanced EGFRm NSCLC
15:00 - 15:15
![Hamed](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/175sDbw1mSHyfkW0zzdv8S30BnWW5jyFzCfKYxNT.png)
Dr. Hamed AlHusaini
Consultant, Medical Oncology
King Faisal Cancer center King Faisal Specialist Hospital and Research Center, Riyadh
Saudi Arabia
![Hamed](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/175sDbw1mSHyfkW0zzdv8S30BnWW5jyFzCfKYxNT.png)
Dr. Hamed AlHusaini
Consultant, Medical Oncology , King Faisal Cancer center King Faisal Specialist Hospital and Research Center, Riyadh | Saudi Arabia
Hamed ALHusaini, MD is the Acting chairman, medical oncology, in King Faisal Specialist Hospital and research center and an Associate Professor, Collage of Medicine, Alfaisal University, Riyadh, Saudi Arabia. He is a medical oncologist currently focusing on management of thoracic cancer and Gynecological malignancies.
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Saturday, 2024-06-29
ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).
09:50 - 10:00
Saturday, 2024-06-29
Panel Discussion and Q&A
10:20 - 10:40
![Hassan](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/9bpf3Lkfsv2n658vqFl9WOWUSozeC1j58EjabnU3.png)
Dr. Hassan Ghazal
Consultant Medical Oncologist & Consultant Clinical Hematologist
King's College Hospital London
United Arab Emirates
![Hassan](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/9bpf3Lkfsv2n658vqFl9WOWUSozeC1j58EjabnU3.png)
Dr. Hassan Ghazal
Consultant Medical Oncologist & Consultant Clinical Hematologist , King's College Hospital London | United Arab Emirates
Dr Hassan Ghazal is an American board-certified Consultant Medical Oncologist and a Consultant Clinical hematologist offering more than 3 decades of clinical experience. Dr Hassan Ghazal, after doing his basic medical education in American University of Beirut, moved to US for his residency program in Internal Medicine at Sinai Hospital of Baltimore, MD. In 1992, completing the residency program, Dr Hassan Ghazal joined in George Washington university Medical Center for his fellowship in Medical Oncology and completed the same in 1995. He continued in George Washington University Medical Center for another 2 years and obtained his senior fellowship in bone marrow transplantation in the year 1997. He got his US board certification in Internal Medicine, Medical Oncology and in Hematology in the year 1992, 1995,1996 respectively. Except his association with CMC for the preceding 3 years, all his clinical practices were in US in various capacities including Director, Kentucky Cancer Clinic and Staff Oncologist/ Hematologist at Hazard Appalachian Regional Medical Center. Dr Hassan Ghazal is a member of various clinical societies such as American College of Physicians, American Society of Haematology, American Society of Clinical Oncology, European Society of Medical Oncology etc. Dr Hassan Ghazal has got many publications and abstracts in his credit, in peer reviewed journals, and there are many international recognitions and accolades in his name. He has been involved in numerous clinical trials, nearly 100, in the US, serving as Principal Investigator, for over 25 years, and enrolled hundreds of patients in these trials.
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Saturday, 2024-06-29
Breast Cancer Workshop 1- HER-2 Positive Early Breast Cancer - Optimising Treatment Options (Supported by Roche)
16:00 - 17:00
Sunday, 2024-06-30
Lung Cancer Workshop 1 - Targeted therapy for a NSCLC- Focus on ALK Inhibition (Supported by Pfizer)
11:30 - 12:30
Lectures by this speaker
Saturday, 2024-06-29
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.
11:50 - 12:00
Saturday, 2024-06-29
Panel Discussion and Q&A
12:30 - 12:50
Sunday, 2024-06-30
Targeted Therapy for aNSCLC ALK Inhibition: Start Strong for Front Line Therapy
11:30 - 11:50
![Hatoon](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/ukOK38MawUx5qTH2HQnN0p3NXtFZVWjUnRDUWZhB.png)
Dr. Hatoon Bakhribah
Consultant, Adult Medical Oncology
King Fahad Medical City Comprehensive Cancer Center
Saudi Arabia
![Hatoon](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/ukOK38MawUx5qTH2HQnN0p3NXtFZVWjUnRDUWZhB.png)
Dr. Hatoon Bakhribah
Consultant, Adult Medical Oncology , King Fahad Medical City Comprehensive Cancer Center | Saudi Arabia
Dr. Hatoon Bakhribah is a Consultant Medical Oncologist at King Fahad Medical City (KFMC) Riyadh, Saudi Arabia focused on Head & Neck Cancers, Thoracic Malignancies, Skin & Brain Cancers. She earned her medical degree at the M.D. King AbdulAziz University, Faculty of Medicine, Jeddah, Saudi Arabia from 1996 till 2001. Her career magnitudes years functioning as a junior physician back in the day as an Intern in King Khalid National Guard Hospital from 2001-2002, as Resident and Senior Registrar in Prince Sultan Medical City from 2002-2011. After she became an Internal Medicine Consultant in King Saud Medical Complex, Riyadh in year 2011, Dr. Bakhribah has completed her 3 years fellowship in Advanced Hematology/Oncology at Roswell Park Cancer Institute, NY, USA from 2013 till 2016 and obtained her certificate in July 2016. After her fellowship, she returned as a Sub-Specialty Consultant and worked in a private institution for a year (2016-2017) in the Kingdom of Saudi Arabia and afterwards she joined King Fahad Medical City as a Sub-Specialty Consultant specializing on Head & Neck Cancers, Thoracic malignancies, Skin & Brain Cancers in December 2017. Dr. Bakhribah holds numerous leadership appointment such as; Program Director of Adult Medical Oncology Fellowship from September 2018 till September 2020; CCC Mortality & Morbidity Committee Chairperson from January 2018 till August 2021 and currently the Chairperson of Quality Improvement Committee in Cancer Center, KFMC.
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
Panel Discussion and Q&A
10:25 - 10:55
Sunday, 2024-06-30
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12Cmutation.
09:40 - 09:50
![Husam](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/q2txAVF8ChSQNzkTOMCBNMA7QlQFSX8jYL6Fm05t.png)
Dr. Husam Marashi
Consultant Medical Oncologist
Tawam Hospital
United Arab Emirates
![Husam](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/q2txAVF8ChSQNzkTOMCBNMA7QlQFSX8jYL6Fm05t.png)
Dr. Husam Marashi
Consultant Medical Oncologist , Tawam Hospital | United Arab Emirates
Dr. M Husam Marashi, a dedicated Medicine specialist at Tawam Hospital, with a focus on General Oncology. Dr. Marashi specializes in Breast, GI, and Head & Neck Cancers. His expertise lies in comprehensive oncological care, ensuring patients receive tailored treatment. With a commitment to staying abreast of advancements, Dr. Marashi plays a crucial role in the multidisciplinary approach to cancer treatment. His empathetic approach and specialized knowledge make him an invaluable asset in the field of Medicine, particularly in the challenging realm of oncology.
Sessions by this speaker
Saturday, 2024-06-29
Session 1: Plenary
09:40 - 11:00
Saturday, 2024-06-29
Session 3: Early Breast Cancer
14:00 - 16:00
Saturday, 2024-06-29
Tawam Faculty
09:00 - 15:30
Saturday, 2024-06-29
Breast Cancer Workshop 1- HER-2 Positive Early Breast Cancer - Optimising Treatment Options (Supported by Roche)
16:00 - 17:00
Saturday, 2024-06-29
Breast Cancer Workshop 2 - Optimizing Therapeutic Selection and Sequencing Post CDK 4/6 Inhibition (Supported by Menarini Stemline)
17:00 - 18:00
Sunday, 2024-06-30
Breast Cancer Workshop 3 - Exploring the potential of ADCs in Breast Cancer (Supported by Gilead)
09:30 - 10:30
Friday, 2024-06-28
Oncology Fellowship Masterclass
14:00 - 19:00
Lectures by this speaker
Saturday, 2024-06-29
Panel Discussion and Q&A
10:20 - 10:40
Saturday, 2024-06-29
CAPItello-291 Unlocking TRU potential for (HR)+ mBC (Satellite Symposium by AstraZeneca)
11:00 - 11:20
Saturday, 2024-06-29
Panel Discussion and Q&A
15:20 - 15:40
Saturday, 2024-06-29
Panel Discussion and Q&A
12:30 - 12:50
Saturday, 2024-06-29
Novel approach with Dual IO for the management of HCC (Satellite Symposium - BMS)
16:50 - 17:10
Saturday, 2024-06-29
Panel Discussion and Q&A
17:10 - 17:25
Saturday, 2024-06-29
S/C vs IV Anti-HER2 therapy: Preferences and Challenges
16:05 - 16:10
Saturday, 2024-06-29
Introduction: Advance Breast Cancer HR-positive: Unmet Needs
17:00 - 17:05
Sunday, 2024-06-30
Improving the Lives of Patients with mTNBC and Metastatic HR+ Breast Cancer: Safety Standpoint
10:00 - 10:10
Sunday, 2024-06-30
Debate Topic: Balancing Innovation and Safety: Navigating the Safety Seas of ADCs in Breast Cancer Treatment Clinical Scenario
10:10 - 10:30
![Ikram](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/6y0Sw1NFn4wytyMOyEaylkOxp94tFDJv5HwjRH9d.png)
Dr. Ikram Burney
Senior Consultant in Medical Oncology
Sultan Qaboos Comprehensive Cancer Care and Research Center
Oman
![Ikram](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/6y0Sw1NFn4wytyMOyEaylkOxp94tFDJv5HwjRH9d.png)
Dr. Ikram Burney
Senior Consultant in Medical Oncology , Sultan Qaboos Comprehensive Cancer Care and Research Center | Oman
Dr Ikram Burney is a Senior Consultant in Medical Oncology at the Sultan Qaboos Comprehensive Cancer Care and Research Center, Muscat, Oman, and Director of the Women Health Program. He completed his residency in medicine and fellowship training in Oncology at the Aga khan University Hospital, and Southampton Hospital NHS trust. He worked as a consultant in Medical Oncology at the Aga Khan University Hospital, Karachi, then at the Sultan Qaboos University Hospital, Muscat, Oman, and now at the SQCCCRC. He is also a visiting faculty at the Panjwani Center for Molecular Medicine and Drug Research, ICCBS, Karachi University, Karachi, Pakistan. Dr Burney has more than 170 publications in peer-reviewed journals, with more than 1900 citations, h-index 24, and i10-index 52. Besides several other research grants, he received the prestigious His Majesty’s Trust Fund research grant in 2017. He has been a co-supervisor for 5 PhD, 8 Master’s, 4 postgraduate residents, and more than 20 undergraduate medical students. He has participated in several clinical trials as the principal investigator for AHUH and SQUH sites. Dr Burney served as the coordinator for the clinical phase of the newly implemented Outcome-based curriculum from 2007 – 2013, and as the Chairman of the Curriculum committee CoM&HS, SQU from 2013 to 2021. Dr Burney is committed to provide evidence-based care to his patients, promote, enhance public and primary care physician awareness about various aspects of cancer management, and initiate, and participate in collaborative research projects, and promote opportunities for academic excellence for students at all levels.
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
Gynecological cancers updates
14:30 - 14:40
Sunday, 2024-06-30
Panel Discussion and Q&A
15:20 - 15:30
![Itrat](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/tGOq5ajru3ljZvb2Ty0eSdjZ2hXt5OunCSnpkZ5Y.png)
Dr. Itrat Mehdi
Consultant Medical Oncologist
National Oncology Centre, The Royal Hospital Muscat
Oman
![Itrat](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/tGOq5ajru3ljZvb2Ty0eSdjZ2hXt5OunCSnpkZ5Y.png)
Dr. Itrat Mehdi
Consultant Medical Oncologist , National Oncology Centre, The Royal Hospital Muscat | Oman
Dr. Itrat Mehdi is currently working as Senior Consultant and head of Medical Oncology, National Oncology Center the Royal Hospital Muscat-Oman. He did his medical graduation (MBBS) from Karachi Pakistan in 1986. He had his postgraduate Oncology training in United Kingdom. He has Fellow ships from UK (FRCP – Edinburgh, FRCP London and FRCP – Glasgow), and PhD from London. He has a vast experience in Oncology practice, and clinical research. He is member of many international organizations like ASCO, ESMO, ESACC, OSO, etc. He is on editorial board of many international and indexed clinical journals like BMJ, JPMA, JPMR, World Journal series, SQUMJ, OMJ, J Nephrology Urology and Transplant, biomarkers, and biochemistry. He has been part of many collaborative research studies and clinical trials. He has supervised more than 10 postgraduate students in their postgraduate studies. He has been an examiner in postgraduate examinations in Oncology. He has attended and presented numerous papers/posters in local and international meetings. He has 81 publications in local and international journals.
Sessions by this speaker
Saturday, 2024-06-29
Session 2: Advanced Breast Cancer
11:00 - 14:00
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Saturday, 2024-06-29
Panel Discussion and Q&A
12:30 - 12:50
![Jawaher](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/BwD0a9hvvPWVODXih8abcqnIVz6RmrZn9hxH9e72.png)
Dr. Jawaher Ansari
Chief of Medical Oncology
Tawam Hospital
United Arab Emirates
![Jawaher](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/BwD0a9hvvPWVODXih8abcqnIVz6RmrZn9hxH9e72.png)
Dr. Jawaher Ansari
Chief of Medical Oncology , Tawam Hospital | United Arab Emirates
Dr Jawaher Ansari completed his Clinical Oncology specialist training in Birmingham, UK and worked as a Consultant at the Beatson Cancer Centre in Glasgow, the second largest cancer center in the UK, prior to moving to the Middle East. Dr Ansari has been a principal investigator for several international clinical trials and has authored several peer-reviewed publications and textbook chapters. He has a specialist interest in Urology, Breast and Lung cancers.
Sessions by this speaker
Saturday, 2024-06-29
Tawam Faculty
09:00 - 15:30
Saturday, 2024-06-29
GU Workshop - Theranostics: The future of Prostate cancer treatment is here! (Supported by Novartis)
11:30 - 12:30
Friday, 2024-06-28
Oncology Fellowship Masterclass
14:00 - 19:00
Lectures by this speaker
Saturday, 2024-06-29
CAPItello-291 Unlocking TRU potential for (HR)+ mBC (Satellite Symposium by AstraZeneca)
11:00 - 11:20
Saturday, 2024-06-29
Introduction: PSMA PET revolution in prostate cancer | Potential for false positives
11:30 - 11:35
Saturday, 2024-06-29
Case 1- Optimal timing for PSMA RLT therapy
11:45 - 11:50
Saturday, 2024-06-29
Case 3- Predicting response to 177Lu-PSMA-617 therapy
12:15 - 12:20
Friday, 2024-06-28
Welcome And Introductory Remarks
14:20 - 14:30
![Lorenza](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/4NnXI5sgWPAGZbJFi0LTBfTdB6IflBaA9pMmUvQb.png)
Dr. Lorenza Landi
Director of Clinical Trials Unit: Phase 1 and Precision Medicine
National Cancer Institute “Regina Elena”
Italy
![Lorenza](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/4NnXI5sgWPAGZbJFi0LTBfTdB6IflBaA9pMmUvQb.png)
Dr. Lorenza Landi
Director of Clinical Trials Unit: Phase 1 and Precision Medicine , National Cancer Institute “Regina Elena” | Italy
"Dr Lorenza is a Medical Oncology - Director of Clinical Trials Unit: Phase 1 and Precision Medicine in National Cancer Institute “Regina Elena”, Italy. - Born in Chianciano Terme (Italy) on October 5th, 1978, Lorenza Landi graduated, summa cum laude, in medicine and surgery at the Pisa University in October 2004. - In November 2008 Degree summa cum laude in Medical Oncology at Pisa University. - From October 2001 to September 2004 internship at the Department of Medical Oncology of Istituto Toscano Tumori in Livorno. - From November 2004 to November 2008 specialist registrar training program in medical oncology at the University of Pisa. - From January 2009 to March 2011 Fellowship in Medical Oncology at the Department of Medical Oncology of Istituto Toscano Tumori in Livorno. - From April 2011 to April 2017 Medical Oncologist at the Department of Medical Oncology of Istituto Toscano Tumori in Livorno. - From May 2017 to October 2020 Medical Oncologist at the Department of Medical Oncology of Azienda AUSL della Romagna, in Ravenna. - From November 2020 to April 2022 Medical Oncologist at the “Regina Elena” National Cancer Institute, Medical Oncology Unit, in Rome - Since May 2022 Director of Clinical Trials Unit: Phase 1 and Precision Medicine, “Regina Elena” National Cancer Institute, Rome"
Sessions by this speaker
Saturday, 2024-06-29
International Speakers
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
Panel Discussion and Q&A
10:25 - 10:55
Sunday, 2024-06-30
Lorlatinib in first line treatment of ALK +ve aNSCLC (Satellite Symposium by Pfizer)
09:50 - 10:10
Sunday, 2024-06-30
Targeted Therapy for aNSCLC ALK Inhibition: Start Strong for Front Line Therapy
11:30 - 11:50
Sunday, 2024-06-30
Navigating the Treatment Landscape: Case Presentation
12:00 - 12:20
![Majid](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/P4wAaIgeCtDyEudoDGEkTh6CbDNndRiGk0sqWurO.png)
Dr. Majid Al Jahil
Medical Oncology Consultant, Director of Oncology Center
King Salman bin Abdulaziz Medical City
Saudi Arabia
![Majid](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/P4wAaIgeCtDyEudoDGEkTh6CbDNndRiGk0sqWurO.png)
Dr. Majid Al Jahil
Medical Oncology Consultant, Director of Oncology Center , King Salman bin Abdulaziz Medical City | Saudi Arabia
Consultant Of Internal medicine and Medical Oncology in King Salman bin Abdulaziz Medical city - Madinah Associate Executive Director of Oncology & Hematology Center in King Salman bin Abdulaziz Medical city - Madinah Vice President of the Saudi Oncology Society SOS
Sessions by this speaker
Saturday, 2024-06-29
Session 4: Gastrointestinal Cancers
16:00 - 17:50
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Saturday, 2024-06-29
Panel Discussion and Q&A
17:10 - 17:25
![Mariam](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/MNNGKOrDQjOtTaDmcnHIIavABuYJ0bK0Uzs8IlR2.png)
Dr. Mariam Almarashda
Consultant Thoracic Surgeon
Tawam Hospital
United Arab Emirates
![Mariam](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/MNNGKOrDQjOtTaDmcnHIIavABuYJ0bK0Uzs8IlR2.png)
Dr. Mariam Almarashda
Consultant Thoracic Surgeon , Tawam Hospital | United Arab Emirates
Dr. Mariam Almarashda MBBS ABHS (CTh) was graduated from College of Medicine and Health Sciences, UAE University, in 2006. Finished her Arab board training in General Surgery 2013 from The General Surgery Integrated program in the Emirate of Abu Dhabi, UAE. Followed by Clinical Fellowship in Thoracic Surgery in Vanderbilt University, Tennessee, USA with clinical Research fellowship in Both Lung cancer and Oesophageal Cancer, in 2016. She was appointed as Consultant Thoracic Surgeon in SEHA in September 2016. She is Associate Professor in UAE University College of Medicine & Health Sciences. She has held several senior management role and organizer of international workshops in advanced thoracic surgical techniques including Chest wall trauma Surgery. Beside her Clinical Leadership, she has Special Interest in Medical Education, She is the Lead of ACGME- I Surgical training Program in Emirates of Abu Dhabi since 2013. Program Director of the integrated General Surgery Program since 2017. She is the Chair of Scientific committee for Surgical Programs for the NIHS Emirati board in UAE and Lead of Surveyor’s for Both NIHS Institutional and Program accreditation in the Country.
Sessions by this speaker
Sunday, 2024-06-30
Session 5: Lung Cancer
09:00 - 11:15
Saturday, 2024-06-29
Tawam Faculty
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
Panel Discussion and Q&A
10:25 - 10:55
![Maroun](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/GhY0L1S2M7jQLVqcII00vEnYVgtORIsVej1dr9TF.png)
Dr. Maroun El Khoury
Consultant Oncologist / Hematologist
American Hospital
United Arab Emirates
![Maroun](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/GhY0L1S2M7jQLVqcII00vEnYVgtORIsVej1dr9TF.png)
Dr. Maroun El Khoury
Consultant Oncologist / Hematologist , American Hospital | United Arab Emirates
Assistant Professor Doctor Maroun El Khoury Consultant Oncologist/ Hematologist at American Hospital in Dubai 9/2010-Present. Mayo Clinic Network (Jci Accredited), Director Of Cancer Care Center, President of Medical Staff: 2018-2020. Chairperson Scientific Committee, Emirates Oncology Society: 2018-2020 .7/2006-8/2010: Private Practice In The Us/Iowa: Medical Director Of Oncology And Hematology Services And Chief Of Medicine At Great River Health System .7/2006-2010: Hospice Medical Co-Director .Epec (Education In Palliative And End-Of-Life Care) Trainer.
Sessions by this speaker
Sunday, 2024-06-30
Session 5: Lung Cancer
09:00 - 11:15
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Sunday, 2024-06-30
Lung Cancer Workshop 1 - Targeted therapy for a NSCLC- Focus on ALK Inhibition (Supported by Pfizer)
11:30 - 12:30
Lectures by this speaker
Sunday, 2024-06-30
Panel Discussion and Q&A
10:25 - 10:55
Sunday, 2024-06-30
Navigating the Treatment Landscape: Case Presentation
12:00 - 12:20
![Meteb](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/wNez8zmBCQXPc6fs7je87LMV0LOefTBqVnWNnJSL.png)
Dr. Meteb Alfoheidi
Medical Oncology Consultant – Breast Cancer
Princess Noorah Oncology Center – National Guard Health Affairs, Jeddah
Saudi Arabia
![Meteb](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/wNez8zmBCQXPc6fs7je87LMV0LOefTBqVnWNnJSL.png)
Dr. Meteb Alfoheidi
Medical Oncology Consultant – Breast Cancer , Princess Noorah Oncology Center – National Guard Health Affairs, Jeddah | Saudi Arabia
Medical Oncology Consultant – Breast Cancer Sub-specialty Princess Noorah Oncology Center – National Guard Health Affairs, Jeddah Assistant Professor & Medical Oncology Block Cordinator King Saud Bin Abdulaziz University for Health and Science – Jeddah Western Oncology Group Director Saudi Oncology Society
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Saturday, 2024-06-29
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.
11:30 - 11:40
Saturday, 2024-06-29
Panel Discussion and Q&A
12:30 - 12:50
![Mohamed](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/5bXRzN6NYpuLs9jwZkvzL8OzXpQmCwX8A3uIYtnk.png)
Dr. Mohamed Ashour
Consultant Medical Oncologist
Kuwait Cancer Control Center
Kuwait
![Mohamed](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/5bXRzN6NYpuLs9jwZkvzL8OzXpQmCwX8A3uIYtnk.png)
Dr. Mohamed Ashour
Consultant Medical Oncologist , Kuwait Cancer Control Center | Kuwait
Dr. Mohamed Ashour is a Consultant Medical Oncologist in Kuwait Cancer Control Center and a Professor in Clinical Oncology at Alzhar University. He received his Cancer research diploma at Harvard University. Dr Mohamed is also a Member of ASCO and ESMO and is interested in GU&GY malignancy. Dr Ashour has many publications in peer review journal.
Sessions by this speaker
Sunday, 2024-06-30
Session 6: Genitourinary Cancers
11:15 - 14:30
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
Panel Discussion and Q&A
12:25 - 13:00
![Mohammed](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/xEknx1GXzT4FaGgs8qcG1Vg2OpSr9JnqopVqLYLh.png)
Dr. Mohammed Hourani
Oncology Fellow
Tawam Hospital
United Arab Emirates
![Mohammed](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/xEknx1GXzT4FaGgs8qcG1Vg2OpSr9JnqopVqLYLh.png)
Dr. Mohammed Hourani
Oncology Fellow , Tawam Hospital | United Arab Emirates
Dr. Mohammad Hourani is a distinguished medical oncologist with an extensive background in internal medicine and oncology. He holds an MBBS degree followed by rigorous training accredited by the American Accreditation Council for Graduate Medical Education (ACGME). Dr. Hourani has earned Arab & Jordanian board in both internal medicine and medical oncology. Further enhancing his expertise, Dr. Hourani has obtained a specialty certificate in medical oncology from the United Kingdom, reflecting his commitment to maintaining a high standard of knowledge and practice in the field. Dr. Hourani is dedicated to advancing the field of oncology through both clinical practice and research. He has conducted various researches and has numerous publications under his name.
Sessions by this speaker
Saturday, 2024-06-29
Tawam Faculty
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
Panel Discussion and Q&A
15:20 - 15:30
![Muath](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/mKNJMLuMNhSZQPFypJ0S8Y9KK18bSmkuyX6CtyEW.png)
Dr. Muath Nassar
Consultant Medical Oncologist
Kuwait Cancer Control Center
Kuwait
![Muath](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/mKNJMLuMNhSZQPFypJ0S8Y9KK18bSmkuyX6CtyEW.png)
Dr. Muath Nassar
Consultant Medical Oncologist , Kuwait Cancer Control Center | Kuwait
Dr. Muath Alnassar is currently working as head of Thoracic , Head & neck and sarcoma unit at Kuwait Cancer Control Center. He completed residency oncology program from western ontario university in canada 2016
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Sunday, 2024-06-30
Lung Cancer Workshop 1 - Targeted therapy for a NSCLC- Focus on ALK Inhibition (Supported by Pfizer)
11:30 - 12:30
Lectures by this speaker
Sunday, 2024-06-30
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.
09:30 - 09:40
Sunday, 2024-06-30
Panel Discussion and Q&A
10:25 - 10:55
Sunday, 2024-06-30
Navigating the Treatment Landscape: Case Presentation
12:00 - 12:20
![Mudhasir](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/uigT1FsxjOgVruCQVRt3c24KHir4aHfKcWQLR0mp.png)
Dr. Mudhasir Ahmad
Specialist Medical Oncologist
Burjeel Lifecare Hospital Mussafah Abu Dhabi
United Arab Emirates
![Mudhasir](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/uigT1FsxjOgVruCQVRt3c24KHir4aHfKcWQLR0mp.png)
Dr. Mudhasir Ahmad
Specialist Medical Oncologist , Burjeel Lifecare Hospital Mussafah Abu Dhabi | United Arab Emirates
Dr. Mudhasir Ahmad is a Medical Oncologist at Burjeel Lifecare Hospital, Musafffah. He started his career from University of Kashmir, and SKIMS, Srinagar, India. He continued his journey in Oncology and Hematology/Bone marrow transplant from Indraprastha Apollo Hospitals, Delhi, India. He later got his Diplomate of National Board Medical Oncology Fellowship at Apollo Hospitals, Hyderabad, India. He joined Healthcare Global Hospital, Delhi as a Consultant Medical Oncologist and later as Senior Consultant Medical Oncology at Fortis Hospital Noida, Delhi, India.
Sessions by this speaker
Sunday, 2024-06-30
Session 7: Practice Changing Data
14:30 - 15:35
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
Panel Discussion and Q&A
15:20 - 15:30
![Muhammad](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/ucryo1ciiNMTOad0makKrJT1tnldvrQZQd8YsCyk.png)
Dr. Muhammad Nasim
Consultant Physician
Tawam Hospital
United Arab Emirates
![Muhammad](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/ucryo1ciiNMTOad0makKrJT1tnldvrQZQd8YsCyk.png)
Dr. Muhammad Nasim
Consultant Physician , Tawam Hospital | United Arab Emirates
Dr. Muhammad Nasim is a medical oncologist with a patient-centred approach. Throughout his oncology career, he has collaborated with multidisciplinary professionals and scientists to improve clinical outcomes for patients. His team based approach and interdisciplinary communication skills aids the smooth delivery of oncology service at this hospital. He has over 7 years’ experience as consultant Medical oncologist, having gained comprehensive site specific experience in colorectal, Gynae and Carcinoma of unknown primary (CUP), being lead for CUP, Acute Oncology and Chemotherapy subgroup, having set up CUP services at SaTH, and having managed wide variety of patients with malignancies of these tumor sites. He has represented oncology in peer review meetings for CUP and Acute oncology, and in Annual General meetings for colorectal and Gynae.
Sessions by this speaker
Saturday, 2024-06-29
Session 4: Gastrointestinal Cancers
16:00 - 17:50
Saturday, 2024-06-29
Tawam Faculty
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
GI Cancers Updates
15:00 - 15:10
Sunday, 2024-06-30
Panel Discussion and Q&A
15:20 - 15:30
Saturday, 2024-06-29
Panel Discussion and Q&A
17:10 - 17:25
![Munjid](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/xWSpIGfXx2TRcpNocpZtf1lo9EFEKdyv8iN8Nln6.png)
Dr. Munjid Al Harthy
Consultant in Urological Oncology
Sultan Qaboos Comprehensive Cancer Care and Research Centre
Oman
![Munjid](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/xWSpIGfXx2TRcpNocpZtf1lo9EFEKdyv8iN8Nln6.png)
Dr. Munjid Al Harthy
Consultant in Urological Oncology , Sultan Qaboos Comprehensive Cancer Care and Research Centre | Oman
Munjid Al Harthy is a Consultant Medical Oncologist who specializes in the care of patients with genitourinary cancers. He completed his fellowship training in Medical Oncology and Hematology at the National Cancer Institute (NCI)/National Institutes of Health (NIH) in Bethesda, MD, after which he worked as an attending physician and investigator at the NCI on several clinical trials for patients with various malignancies. He currently serves as the head of the GU malignancies program at the Sultan Qaboos Comprehensive Cancer and Research Center (SQCCCRC) in Oman, where he also serves as the head of the clinical trials department.
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore.
11:55 - 12:05
Sunday, 2024-06-30
Panel Discussion and Q&A
12:25 - 13:00
![Nadeem](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/CM6S7pPeeIurVDRFKsModsvNemhm73SHvC4kh2kq.png)
Dr. Nadeem Pervez
Radiation Oncologist
Cross Cancer Institute
Oman
![Nadeem](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/CM6S7pPeeIurVDRFKsModsvNemhm73SHvC4kh2kq.png)
Dr. Nadeem Pervez
Radiation Oncologist , Cross Cancer Institute | Oman
Dr. Nadeem Pervez qualified in Radiation Oncologist from Ireland and Canada. He worked in Ireland, Canada and Middle East at various academic levels. He served as radiation oncologist at Cross Cancer Institute and Associate Professor at University of Alberta, Edmonton, Alberta, Canada. His clinical work includes treating cancer of various sites with emphasis on breast and prostate cancer. He was a prominent member of Prostate Cancer Brachytherapy seed implantation treatment in Canada. He is initiating Prostate Brachytherapy treatment in the Middle East. He co-chaired breast cancer group in Alberta and contributed to Alberta Breast Cancer Treatment guidelines. He was involved in invention of newer radiotherapy machines. Nadeem was actively involved in contributing to Resident Training program and Clinical Research Fellowship program in Radiation Oncology at the University of Alberta, Canada. He was awarded best teacher award from residents to acknowledge his contributions. He oversees research projects from international fellows. His residents and fellows later appointed at key academic, clinical and leadership positions across world. He was invited as scientific speaker in multiple countries. Nadeem is actively involved in clinical research. He was able to secure multiple competitive research grants from awarding agencies. He was leading investigator initiated studies and involved in multi-institutional cooperative group studies. He published multiple research articles in reputed journals. He served in institutional ethics committees, research funds granting agencies, medical student selection committees, oncology conference scientific committee and peer-reviewed several Oncology journals. He is founding member in establishing Middle East Society of Therapeutic Radiation Oncology (MESTRO).
Sessions by this speaker
Sunday, 2024-06-30
Session 5: Lung Cancer
09:00 - 11:15
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
Panel Discussion and Q&A
10:25 - 10:55
![Nouri](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/4bIMJpzId5RpPJB8epBnS0lDZcJqvzDatN85fZvM.png)
Dr. Nouri Bennini
Consultant Oncologist
Tawam Hospital
United Arab Emirates
![Nouri](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/4bIMJpzId5RpPJB8epBnS0lDZcJqvzDatN85fZvM.png)
Dr. Nouri Bennini
Consultant Oncologist , Tawam Hospital | United Arab Emirates
Nouri Bennini has served as Consultant Oncologist at the Tawam Hospital in Al Ain, United Arab Emirates, since 1999. He received his general medicine diploma in 1988 from the University of Constantine in Algeria and undertook residency in medical oncology at the University of Bordeaux, France. At the University of Montpellier, France, Dr Bennini specialised in breast diseases. He has published several scientific papers and contributed to a number of oncology conferences.
Sessions by this speaker
Sunday, 2024-06-30
Session 6: Genitourinary Cancers
11:15 - 14:30
Saturday, 2024-06-29
Tawam Faculty
09:00 - 15:30
Saturday, 2024-06-29
GU Workshop - Theranostics: The future of Prostate cancer treatment is here! (Supported by Novartis)
11:30 - 12:30
Saturday, 2024-06-29
Breast Cancer Workshop 2 - Optimizing Therapeutic Selection and Sequencing Post CDK 4/6 Inhibition (Supported by Menarini Stemline)
17:00 - 18:00
Lectures by this speaker
Sunday, 2024-06-30
Introduction
09:00 - 09:10
Sunday, 2024-06-30
Panel Discussion and Q&A
12:25 - 13:00
Sunday, 2024-06-30
Dual IO in 1L NSCLC Treatment (Satellite Symposium by BMS)
10:10 - 10:25
Saturday, 2024-06-29
EMERALD Study, Efficacy Data, Safety Profile
17:20 - 17:30
![Omran](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/QUcVYdV9QiEsx1XJIHnYbJ9FkuoUaAgnpy2kIDoW.png)
Dr. Omran El Koha
Consultant Radiation / Clinical Oncologist
Tawam Hospital
United Arab Emirates
![Omran](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/QUcVYdV9QiEsx1XJIHnYbJ9FkuoUaAgnpy2kIDoW.png)
Dr. Omran El Koha
Consultant Radiation / Clinical Oncologist , Tawam Hospital | United Arab Emirates
Dr. Omran is an experienced clinical oncologist with a demonstrated history of working in the medical and radiation oncology p . Skilled in Clinical Research, Medical Education, Strategic Planning. Strong education professional with a Master's Degree focused in Health research ethics
Sessions by this speaker
Sunday, 2024-06-30
Session 7: Practice Changing Data
14:30 - 15:35
Saturday, 2024-06-29
Tawam Faculty
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
Panel Discussion and Q&A
15:20 - 15:30
![Rana](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/dyUuKNXkZj8gE5AMu9phxzfUOG5xf70f51bE2OxP.png)
Dr. Rana Mahmood
Consultant Oncologist
Mediclinic City Hospital
United Arab Emirates
![Rana](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/dyUuKNXkZj8gE5AMu9phxzfUOG5xf70f51bE2OxP.png)
Dr. Rana Mahmood
Consultant Oncologist , Mediclinic City Hospital | United Arab Emirates
Dr Rana Mahmood trained in UK and has been a consultant in oncology for last 15 years. Dr Mahmood has special interest in advance image guided radiotherapy, SABR and image based High Dose rate Brachytherapy. He is the first to introduce and only practitioner to provide Gynaecological interstitial brachytherapy in UAE. He has setup the only service in UAE to provide prostate Brachytherapy and trans-perineal spacer device. He has been principal investigator for several landmark radiotherapy trials and extensively published his work.
Sessions by this speaker
Sunday, 2024-06-30
Session 7: Practice Changing Data
14:30 - 15:35
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Saturday, 2024-06-29
GU Workshop - Theranostics: The future of Prostate cancer treatment is here! (Supported by Novartis)
11:30 - 12:30
Lectures by this speaker
Sunday, 2024-06-30
Panel Discussion and Q&A
15:20 - 15:30
![Saeed](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/AgX2eBT2uUFU3ds7nPYV5O9vFYG3CTsnqvhVuBNP.png)
Dr. Saeed Rafii
Medical Oncologist
Mediclinic Middle East
United Arab Emirates
![Saeed](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/AgX2eBT2uUFU3ds7nPYV5O9vFYG3CTsnqvhVuBNP.png)
Dr. Saeed Rafii
Medical Oncologist , Mediclinic Middle East | United Arab Emirates
Dr. Saeed Rafii is a UK trained and board certified consultant medical oncologist. After completion of his primary medical degree he was trained in internal medicine followed by subspeciality training in medical oncology in two of the most prestigious cancer hospitals in the UK, Queen Elizabeth Hospital Birmingham and the Royal Marsden Hospital, London. He then completed clinical fellowship in early phase clinical trials at the Royal Marsden Hospital, London and received his CCT (certificate of completion of training) from the UK General Medical Council. Dr Rafii was subsequently appointed as associate professor and consultant in medical oncology at the University of Manchester and the Christie hospital, one of the largest cancer hospitals in Europe, where he helped to establish and expand the Experimental Cancer Medicine Centre. He then moved to University College London Hospital and Oxford cancer network as a consultant medical oncologist. He has an extensive expertise in clinical trials and has been Chief, Principal or Co-investigator on over 100 early and late phase oncology clinical trials. Dr Rafii also holds a PhD and a postdoctoral fellowship in molecular cancer genetics. He is a member of the Royal College of Physicians of the UK, European Society of Medical Oncology (ESMO) and American Association for Clinical Oncology (ASCO). In 2018 he was elected as Fellow of the Royal College of Physicians of UK (FRCP) for his outstanding medical and research activities.
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Sunday, 2024-06-30
Lung Cancer Workshop 1 - Targeted therapy for a NSCLC- Focus on ALK Inhibition (Supported by Pfizer)
11:30 - 12:30
Sunday, 2024-06-30
Lung Cancer Workshop 2: Transforming the Current Treatment Paradigm in The Management of EGFRm NSCLC for Better Survival Outcomes (Supported by AstraZeneca)
14:30 - 16:00
Lectures by this speaker
Saturday, 2024-06-29
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
14:30 - 14:40
Saturday, 2024-06-29
Panel Discussion and Q&A
15:20 - 15:40
Sunday, 2024-06-30
Panel Discussion
14:45 - 15:00
Sunday, 2024-06-30
Navigating the Treatment Landscape: Case Presentation
12:00 - 12:20
![Selvaraj](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/Fdxem4lei0yW4FYDoaZRevOgwAoFNp5SKmU76cdX.png)
Dr. Selvaraj Giridharan
Consultant Clincial Oncologist
Tawam Hospital
United Arab Emirates
![Selvaraj](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/Fdxem4lei0yW4FYDoaZRevOgwAoFNp5SKmU76cdX.png)
Dr. Selvaraj Giridharan
Consultant Clincial Oncologist , Tawam Hospital | United Arab Emirates
Dr. Selvaraj Giridharan is a distinguished oncologist trained extensively in the UK with dual certification in radiation and medical oncology. With over 20 years of experience in tertiary and university hospital settings, he has significantly contributed to acute oncology, inpatient and outpatient care, and clinical research. Currently serving as a Consultant Medical Oncologist at Tawam Hospital, UAE, Dr. Giridharan has demonstrated exceptional skills in managing diverse patient demographics and navigating cultural nuances in cancer care. Dr Giridharan's academic journey includes a PhD and MSc in Yoga, alongside numerous certifications from prestigious institutions such as the Royal College of Radiologists, Royal College of Physicians, and European Society of Medical Oncology. His research interests are reflected in his robust publication record and active participation in clinical trials, where he has served as Principal Investigator and Sub-Investigator in over 30 randomized trials. A dedicated educator, Dr. Giridharan has held various teaching roles, including Honorary Senior Lecturer at Keele University Medical School. His leadership in multidisciplinary teams and commitment to clinical governance and quality improvement have been pivotal in enhancing healthcare outcomes. Passionate about integrating holistic approaches into cancer care, Dr. Giridharan is also deeply involved in yoga and yoga research exploring the therapeutic benefits of yoga for cancer patients, aiming to improve their quality of life and overall well-being.
Sessions by this speaker
Saturday, 2024-06-29
Session 1: Plenary
09:40 - 11:00
Saturday, 2024-06-29
Tawam Faculty
09:00 - 15:30
Sunday, 2024-06-30
Lung Cancer Workshop 1 - Targeted therapy for a NSCLC- Focus on ALK Inhibition (Supported by Pfizer)
11:30 - 12:30
Sunday, 2024-06-30
Lung Cancer Workshop 2: Transforming the Current Treatment Paradigm in The Management of EGFRm NSCLC for Better Survival Outcomes (Supported by AstraZeneca)
14:30 - 16:00
Friday, 2024-06-28
Oncology Fellowship Masterclass
14:00 - 19:00
Lectures by this speaker
Saturday, 2024-06-29
Panel Discussion and Q&A
10:20 - 10:40
Saturday, 2024-06-29
Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial.
16:10 - 16:20
Saturday, 2024-06-29
Panel Discussion and Q&A
17:10 - 17:25
Sunday, 2024-06-30
Targeted Therapy for aNSCLC ALK Inhibition: Start Strong for Front Line Therapy
11:30 - 11:50
Sunday, 2024-06-30
Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.
09:10 - 09:20
![Shaheenah](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/dF074zopViyoWG8u8B6aGkaC41KzoO29g9KaLs9A.png)
Dr. Shaheenah Dawood
Consultant Medical Oncologist, Adjunct Clinical Professor
Mohammed Bin Rashid University of Medicine and Health Sciences
United Arab Emirates
![Shaheenah](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/dF074zopViyoWG8u8B6aGkaC41KzoO29g9KaLs9A.png)
Dr. Shaheenah Dawood
Consultant Medical Oncologist, Adjunct Clinical Professor , Mohammed Bin Rashid University of Medicine and Health Sciences | United Arab Emirates
Dr Shaheenah Dawood is a Consultant Medical Oncologist and Professor in Clinical Oncology in the United Arab Emirates. She was trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training, she was awarded multiple scholar training awards besides ASCO merit awards. Dr Shaheenah has served as an editorial fellow at the New England Journal of Medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles, and 12 book chapters.
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Saturday, 2024-06-29
Session 1: Plenary
09:40 - 11:00
![Sharif](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/zmrUbyOKopsAgdo8a8jucIhu8LO2jHHzIidKIFRP.png)
Dr. Sharif Kullab
Consultant Medical Oncology
King Saud University Medical City
Saudi Arabia
![Sharif](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/zmrUbyOKopsAgdo8a8jucIhu8LO2jHHzIidKIFRP.png)
Dr. Sharif Kullab
Consultant Medical Oncology , King Saud University Medical City | Saudi Arabia
Dr. Sharif Kullab is Consultant Medical Oncologist, and Program Director for Adult Medical Oncology : King Saud University/ Riyadh. Working at Oncology Center / King Saud University Medical City (KSUMC) since June 2016. After his “MD Medical Thesis” in 2006, he did his medical training in the Field of Medical Oncology, and Fellowship at Jean Perrin Comprehensive Cancer Center (CJP) in Clermont Ferrand / France. • He has full registration at The French General Medical Council since 2015. • Worked as consultant medical oncology at CJP/ Clermont Ferrand • Then he was Head of Department of Oncology at Moulins Hospital in France. • During his working in France, he was actively participating in clinical researches and was investigator / coinvestigator in different national and international clinical trials
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
Breast cancer updates
14:40 - 14:50
Sunday, 2024-06-30
Panel Discussion and Q&A
15:20 - 15:30
![Syed](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/zUyOA0OTBgJBIIg1SXyg3BUa6SC47BsnqHQx2xXQ.png)
Dr. Syed Hammad Tirmazy
Consultant Clinical Oncologist
Dubai Hospital
United Arab Emirates
![Syed](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/zUyOA0OTBgJBIIg1SXyg3BUa6SC47BsnqHQx2xXQ.png)
Dr. Syed Hammad Tirmazy
Consultant Clinical Oncologist , Dubai Hospital | United Arab Emirates
Dr Syed Hammad Tirmazy is a Consultant Clinical Oncologist and Head of Oncology at Dubai Hospital, DHA. He has substantive experience in managing adult solid cancers and has been involved in multiple international clinical trials. Before moving to Dubai in 2016, he was working as Consultant Clinical Oncologist in west midlands region UK. After completing his graduation, he moved to UK in 2003, he initially completed internal medicine training and MRCP and subsequently attained training in Clinical Oncology and worked in internationally renowned oncology centers in UK including Queen Elizabeth Hospital Birmingham. He completed Master’s in Clinical Oncology from university of Birmingham, FRCR Clinical Oncology from RCR London and has CCT in Clinical Oncology. He also attained FRCP Glasgow.
Sessions by this speaker
Saturday, 2024-06-29
Regional Speakers
09:00 - 15:30
Saturday, 2024-06-29
GU Workshop - Theranostics: The future of Prostate cancer treatment is here! (Supported by Novartis)
11:30 - 12:30
Saturday, 2024-06-29
Breast Cancer Workshop 1- HER-2 Positive Early Breast Cancer - Optimising Treatment Options (Supported by Roche)
16:00 - 17:00
Sunday, 2024-06-30
Lung Cancer Workshop 2: Transforming the Current Treatment Paradigm in The Management of EGFRm NSCLC for Better Survival Outcomes (Supported by AstraZeneca)
14:30 - 16:00
Lectures by this speaker
Saturday, 2024-06-29
Prospective RCT phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial).
09:40 - 09:50
Saturday, 2024-06-29
Panel Discussion and Q&A
10:20 - 10:40
Saturday, 2024-06-29
Case 2- Managing special populations for 177Lu-PSMA-617 therapy
12:00 - 12:05
Sunday, 2024-06-30
Panel Discussion
15:20 - 15:55
![Syed](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/2ugD1oeYa6Qs8BQ9oG2aiKhDYWnNxLS0XmsVksJW.png)
Prof. Syed Hussain
Professor and Consultant in Medical Oncology
University of Sheffield
United Kingdom
![Syed](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/2ugD1oeYa6Qs8BQ9oG2aiKhDYWnNxLS0XmsVksJW.png)
Prof. Syed Hussain
Professor and Consultant in Medical Oncology , University of Sheffield | United Kingdom
Professor Hussain graduated from Dow Medical College Karachi in 1994. He completed his general medical professional training in UK. He did his Doctorate in Oncology from University of Birmingham. He then completed his Medical oncology training in Birmingham, United Kingdom and received his certification and specialist registration in Medical oncology. Professor Hussain is Professor and Consultant in Medical Oncology at the University of Sheffield and Sheffield Teaching Hospitals NHS Trust. His major areas of interest are management of urological cancers, clinical trials, early drug development and translational medicine. He has set up large number of clinical trials from early phase to late phase studies during his career. His work on organ preservation in bladder cancer moved all the way from an early phase I study (Hussain et al Annals of Oncology 2001) to phase II efficacy study (Hussain et al BJC 2004) that led to a Cancer Research UK funded study BC2001 trial that was reported in New England Journal of Medicine (James, Hussain, Hall et al April 2012). This study has now changed the standard of care for patients with muscle invasive bladder cancer opting for organ preservation treatment. Professor Hussain is principal investigator of number of studies in urological cancers. He is a chief investigator of a national randomised placebo-controlled phase II neo-adjuvant study in muscle invasive bladder cancer. He served as chief investigator of various early phase trials, and translational studies. Professor Hussain has authored over 105 peer-reviewed publications including 4 book chapters in textbooks of oncology. His Google scholar H-index is 37 with over 8300 citations. He has published in high impact journals including New England Journal of medicine, Lancet, Lancet Oncology, JAMA, JAMA Oncology, Journal of Clinical oncology, European Urology, Annals of Oncology, Nature communications, Clinical Cancer Research, British journal of Cancer. He has been an invited speaker to number of national and international meetings. Professor Hussain has secured funding of over 10 million pounds from funding bodies.
Sessions by this speaker
Saturday, 2024-06-29
International Speakers
09:00 - 15:30
Lectures by this speaker
Sunday, 2024-06-30
Perioperative sacituzumab govitecan (SG) alone or in combination with pembrolizumab (Pembro) for patients with muscle-invasive urothelial bladder cancer (MIBC): SURE-01/02 interim results.
11:15 - 11:25
Sunday, 2024-06-30
Panel Discussion and Q&A
12:25 - 13:00
Friday, 2024-06-28
Bladder Cancer
14:45 - 15:00
![Vandana](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/IaTxA2HKp6bXtttpxQCQIbi5aNyyRTOb9ic6J2lu.png)
Prof. Vandana Abramson
Chair in Breast Cancer, Professor of Medicine, Co-Leader of Breast Cancer Research Program, Breast Cancer Disease Team Leader
Vanderbilt-Ingram Cancer Center, Division of Hematology/Oncology; Vanderbilt University Medical Center
USA
![Vandana](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/IaTxA2HKp6bXtttpxQCQIbi5aNyyRTOb9ic6J2lu.png)
Prof. Vandana Abramson
Chair in Breast Cancer, Professor of Medicine, Co-Leader of Breast Cancer Research Program, Breast Cancer Disease Team Leader , Vanderbilt-Ingram Cancer Center, Division of Hematology/Oncology; Vanderbilt University Medical Center | USA
Dr. Abramson is Professor of Medicine in the Division of Hematology/Oncology. After receiving her B.A. in English and Molecular & Cell Biology at the University of California, Berkeley, she went to medical school at the University of Chicago. Dr. Abramson completed her Internal Medicine Residency at Brigham and Women's Hospital in Boston, MA and Hematology/Oncology training at the University of Pennsylvania in Philadelphia, PA. Dr. Abramson serves as the Principal Investigator on several breast cancer clinical trials at Vanderbilt. She is an active member in the American Society of Clinical Oncology.
Sessions by this speaker
Saturday, 2024-06-29
BASCO 2024 Faculty
09:00 - 15:30
Saturday, 2024-06-29
International Speakers
09:00 - 15:30
Lectures by this speaker
Saturday, 2024-06-29
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).
10:10 - 10:20
Saturday, 2024-06-29
Panel Discussion and Q&A
10:20 - 10:40
![Zartash](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/CW8dZr9Wj0YlIBdJJQcPVgcEXBT0r5gp4s5ESmb0.png)
Dr. Zartash Khan
Infectious Disease Consultant
Zayed Military Hospital
United Arab Emirates
![Zartash](https://index-s3-images-static-content.s3.eu-west-1.amazonaws.com/images/speakers/CW8dZr9Wj0YlIBdJJQcPVgcEXBT0r5gp4s5ESmb0.png)
Dr. Zartash Khan
Infectious Disease Consultant , Zayed Military Hospital | United Arab Emirates
Dr Zartash is an American Board Certified in Infectious Diseases and Internal Medicine. Dr Zartash Graduated from Quaid-e-Azam Medical College in Pakistan and completed residency in Internal Medicine from University of Kansas-School of Medicine, and fellowship in Infectious diseases from University of Oklahoma. She is a Fellow of American college of physicians and a member of infectious disease society of America with over 10 years of experience working as Infectious disease consultant. She is Currently working at Zayed Military Hospital as Infectious Disease Consultant.